Jove
Visualize
Contáctanos
JoVE
x logofacebook logolinkedin logoyoutube logo
ACERCA DE JoVE
Visión GeneralLiderazgoBlogCentro de Ayuda JoVE
AUTORES
Proceso de PublicaciónConsejo EditorialAlcance y PolíticasRevisión por ParesPreguntas FrecuentesEnviar
BIBLIOTECARIOS
TestimoniosSuscripcionesAccesoRecursosConsejo Asesor de BibliotecasPreguntas Frecuentes
INVESTIGACIÓN
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchivo
EDUCACIÓN
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualCentro de Recursos para ProfesoresSitio de Profesores
Términos y Condiciones de Uso
Política de Privacidad
Políticas

Videos de Conceptos Relacionados

Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
Cardiomyopathy I: Introduction and Classification01:25

Cardiomyopathy I: Introduction and Classification

Cardiomyopathy, or CMP, is a group of diseases affecting the myocardial structure, impairing its ability to pump blood effectively. This condition can lead to arrhythmias, heart failure, or sudden cardiac death.Cardiomyopathies are classified into primary and secondary categories:Primary Cardiomyopathy refers to conditions involving only the heart muscle that are often idiopathic (of unknown cause) or genetic. They primarily affect the myocardium without the involvement of other systemic...
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
Cardiomyopathy IV: Restrictive Cardiomyopathy01:29

Cardiomyopathy IV: Restrictive Cardiomyopathy

Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...

También podría leer

Artículos Relacionados

Artículos vinculados a este trabajo por autores compartidos, revista y gráfico de citas.

Ordenar por
Same author

Commotio cordis…once again: Unusual occurrence in a noncontact sport.

HeartRhythm case reports·2024
Same author

Evolving Contemporary Management of Atrial Fibrillation in Hypertrophic Cardiomyopathy.

Circulation·2023
Same author

Analysis of risk stratification and prevention of sudden death in pediatric patients with hypertrophic cardiomyopathy: Dilemmas and clarity.

Heart rhythm O2·2023
Same author

QRS Fragmentation as a Risk Marker for Sudden Death in Hypertrophic Cardiomyopathy.

JACC. Clinical electrophysiology·2023
Same author

Medical and Legal Determinants of Sports Eligibility for Young Competitive Athletes With Cardiovascular Disease.

Journal of the American College of Cardiology·2023
Same author

Commotio Cordis Returns…When We Least Expected It: Cardiac Arrest in A Professional Football Player.

The American journal of cardiology·2023
Same journal

Assisted dying and the silencing of medicine's next generation.

Lancet (London, England)·2026
Same journal

Linguistic pragmatism: a woman with progressive abdominal pain in Thailand.

Lancet (London, England)·2026
Same journal

Medical compartmentalisation: a patient with chromosome 22q11.2 deletion syndrome in Japan.

Lancet (London, England)·2026
Same journal

[<sup>177</sup>Lu]Lu-edotreotide versus everolimus for gastroenteropancreatic neuroendocrine tumours (COMPETE): a phase 3, multicentre, randomised, open-label, superiority trial.

Lancet (London, England)·2026
Same journal

Research priorities for characterising Bundibugyo virus.

Lancet (London, England)·2026
Same journal

Rethinking treatment sequence in advanced gastroenteropancreatic neuroendocrine tumours.

Lancet (London, England)·2026
Ver todos los artículos relacionados

Video Experimental Relacionado

Updated: May 19, 2026

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model
03:45

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model

Published on: August 8, 2022

La cardiomiopatía hipertrófica es una cardiomiopatía hipertrófica.

Barry J Maron1, Martin S Maron

  • 1The Hypertrophic Cardiomyopathy Centers of Minneapolis Heart Institute Foundation, Minneapolis, MN, USA.

Lancet (London, England)
|August 10, 2012
PubMed
Resumen
Este resumen es generado por máquina.

La cardiomiopatía hipertrófica (CMH) es una afección cardíaca hereditaria común que afecta a 1 de cada 500 personas. A pesar de los riesgos como la muerte súbita, los tratamientos efectivos ahora mejoran la calidad de vida y la longevidad de muchas personas diagnosticadas.

Más Videos Relacionados

An Approach to Study Shape-Dependent Transcriptomics at a Single Cell Level
06:02

An Approach to Study Shape-Dependent Transcriptomics at a Single Cell Level

Published on: November 2, 2020

Scanning Electron Microscopy of Macerated Tissue to Visualize the Extracellular Matrix
10:21

Scanning Electron Microscopy of Macerated Tissue to Visualize the Extracellular Matrix

Published on: June 14, 2016

Videos de Experimentos Relacionados

Last Updated: May 19, 2026

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model
03:45

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model

Published on: August 8, 2022

An Approach to Study Shape-Dependent Transcriptomics at a Single Cell Level
06:02

An Approach to Study Shape-Dependent Transcriptomics at a Single Cell Level

Published on: November 2, 2020

Scanning Electron Microscopy of Macerated Tissue to Visualize the Extracellular Matrix
10:21

Scanning Electron Microscopy of Macerated Tissue to Visualize the Extracellular Matrix

Published on: June 14, 2016

Área de la Ciencia:

  • Medicina Cardiovascular La medicina cardiovascular es una especialidad de la salud.
  • Genética La genética.
  • Enfermedades cardiovasculares hereditarias Enfermedades cardiovasculares hereditarias

Sus antecedentes:

  • La cardiomiopatía hipertrófica (CMH) es una enfermedad cardiovascular genética prevalente que afecta a 1 de cada 500 personas.
  • Se deriva de más de 1400 mutaciones en los genes que codifican las proteínas del sarcomero cardíaco.
  • La HCM es una de las principales causas de muerte súbita cardíaca en individuos jóvenes, incluidos los atletas.

Objetivo del estudio:

  • Para revisar la comprensión actual de la cardiomiopatía hipertrófica.
  • Para resaltar los criterios de diagnóstico y las estrategias de tratamiento disponibles.
  • Para discutir la transformación de la gestión de HCM en los últimos 50 años.

Principales métodos:

  • El diagnóstico clínico se basa en la identificación de hipertrofia ventricular izquierda inexplicable a través de ecocardiografía o resonancia magnética cardiovascular.
  • Las estrategias de tratamiento incluyen desfibriladores implantables, medicamentos, miectomía quirúrgica, ablación septal por alcohol y manejo de la fibrilación auricular.
  • Las pruebas genéticas identifican mutaciones, incluso en pacientes sin hipertrofia evidente.

Principales resultados:

  • A pesar de su potencial gravedad, muchas personas con HCM permanecen sin diagnosticar y pueden no experimentar una esperanza de vida significativamente reducida.
  • Existen tratamientos efectivos para prevenir la muerte súbita, controlar los síntomas de la insuficiencia cardíaca y reducir el riesgo de accidente cerebrovascular.
  • Un subconjunto de pacientes con mutaciones genéticas pero sin hipertrofia ventricular izquierda presenta un área para futuras investigaciones.

Conclusiones:

  • La cardiomiopatía hipertrófica ha evolucionado de una condición rara e intratable a una enfermedad genética común con resultados manejables.
  • Las estrategias de gestión actuales ofrecen perspectivas realistas para mejorar la calidad de vida y prolongar la longevidad.
  • Se necesita una investigación continua, particularmente para pacientes con mutaciones genéticas pero sin hipertrofia ventricular izquierda.